APA (7th ed.) Citation

Cardellino, A., Correll, J. R., Martin, M., Gorsh, B., Sapra, S., & Popat, R. (2023). Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study. Frontiers Media S.A.

Chicago Style (17th ed.) Citation

Cardellino, Anna, Julia R. Correll, Mona Martin, Boris Gorsh, Sandhya Sapra, and Rakesh Popat. Patient-reported Experiences During and Following Treatment with Belantamab Mafodotin for Relapsed/refractory Multiple Myeloma in the DREAMM-2 Study. Frontiers Media S.A, 2023.

MLA (9th ed.) Citation

Cardellino, Anna, et al. Patient-reported Experiences During and Following Treatment with Belantamab Mafodotin for Relapsed/refractory Multiple Myeloma in the DREAMM-2 Study. Frontiers Media S.A, 2023.